Addex (ADXN) Q2 2026 Earnings Call Transcript
Addex (ADXN) reported a H1 2026 net loss of CHF 3.5M, with cash reserves of CHF 767K. It raised USD 2.8M in capital and regained rights to its GABAB PAM portfolio. The company expects NTX-253 to complete Phase 1 trials by Q4 2026 and is preparing dipraglurant for Phase 2 trials in post-stroke recovery. Management expressed uncertainty about the company's ability to continue as a going concern.
How this was made
The 30-second read
Why it matters
The H1 2026 earnings release adds new financial metrics and operational updates, marking the first public disclosure of the half‑year results.
Market read
The earnings data is material for investors tracking cash‑burn and financing trends in small‑cap biotech, but its impact is confined to niche market participants.
What to watch
Potential future partnership revenue from regained GABAB PAM rights could improve long‑term outlook.
Background
Addex Therapeutics (ADXN) is a Swiss‑based biotech that trades ADRs on Nasdaq. The company focuses on GABAB positive allosteric modulators for CNS disorders.
Ticker impact
Addex Therapeutics reported H1 2026 net loss of CHF 3.5M, cash runway to Q4 2027 and a USD 2.8M capital raise, providing fresh financial data.
likely modest downside as investors price the loss despite the extended cash runway
Losses are sizable for a micro‑cap, but the new capital raise and runway reduce immediate solvency concerns, limiting upside.
Market effects
Provides a data point on the biotech cash‑burn environment and the viability of ATM financing for small caps.
Limited to Swiss‑listed biotech investors; no broader regional effect.
Minimal, confined to niche biotech investors.
Counterpoint
The cash runway to late 2027 may support a short‑term rally if the market over‑reacts to the loss figure.
Key entities
- companyAddex Therapeutics Ltd
Swiss biotech developing GABAB PAM programs.
- spin‑outNeurosterix
Entity in which Addex holds a 20% equity stake.
